News

Generic pains for AstraZeneca exacerbated by Indian drugmakers

Generic pains for AstraZeneca exacerbated by Indian drugmakers

06-04-2014

Indian generic companies are taking aim at mega blockbusters, and AstraZeneca, the $25.7 billion pharmaceutical…

Asia-PacificAstraZenecaDr Reddy's LaboratoriesFinancialGastro-intestinalsGenericsIndiaMarkets & MarketingNexiumPharmaceuticalPulmicortRanbaxy LaboratoriesRespiratory and PulmonarySymbicortUSAVimovo

Dr Reddy’s expands portfolio in Russia and CIS via in-licensing deals with Cipla and Vitabiotics

26-10-2010

Hyderabad-based Dr Reddy’s Laboratories (DRL; NYSE: RDY), India’s second largest drugmaker,…

Asia-PacificCiplaDermatologicalsDr Reddy's LaboratoriesEuropeGastro-intestinalsLicensingOncologyPharmaceuticalVitabiotics

COMPANY SPOTLIGHT

Menarini

Back to top